Blackhawk Capital Partners LLC Grows Stock Holdings in Harrow, Inc. $HROW

Blackhawk Capital Partners LLC raised its position in shares of Harrow, Inc. (NASDAQ:HROW) by 23.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 134,758 shares of the company’s stock after purchasing an additional 25,337 shares during the period. Harrow makes up approximately 2.5% of Blackhawk Capital Partners LLC’s holdings, making the stock its 11th largest holding. Blackhawk Capital Partners LLC’s holdings in Harrow were worth $6,603,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. SBI Securities Co. Ltd. grew its stake in shares of Harrow by 393.5% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after buying an additional 846 shares during the last quarter. Simplicity Wealth LLC bought a new position in shares of Harrow during the fourth quarter valued at about $289,000. Pictet Asset Management Holding SA bought a new position in shares of Harrow during the fourth quarter valued at about $248,000. UBS Group AG grew its stake in shares of Harrow by 82.0% during the fourth quarter. UBS Group AG now owns 222,362 shares of the company’s stock valued at $10,896,000 after buying an additional 100,160 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Harrow by 2.7% during the fourth quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company’s stock valued at $94,162,000 after buying an additional 50,889 shares during the last quarter. 72.76% of the stock is owned by institutional investors.

Harrow Stock Down 0.5%

NASDAQ HROW opened at $38.04 on Tuesday. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.06. The stock has a market capitalization of $1.42 billion, a PE ratio of -223.75 and a beta of 0.34. Harrow, Inc. has a 1 year low of $24.50 and a 1 year high of $54.85. The business’s 50-day moving average is $37.81 and its 200 day moving average is $42.40.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.31). The firm had revenue of $44.20 million for the quarter, compared to the consensus estimate of $52.43 million. Harrow had a negative net margin of 1.89% and a positive return on equity of 36.51%. During the same period in the previous year, the firm posted ($0.38) earnings per share. Sell-side analysts forecast that Harrow, Inc. will post 0.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. B. Riley Financial reaffirmed a “buy” rating and set a $65.00 price objective (down from $74.00) on shares of Harrow in a research note on Tuesday, April 7th. Cantor Fitzgerald reduced their price objective on Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Weiss Ratings cut Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Harrow in a research note on Thursday, March 19th. Finally, Zacks Research raised Harrow from a “strong sell” rating to a “hold” rating in a research note on Friday, April 3rd. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Harrow has an average rating of “Moderate Buy” and an average target price of $69.86.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.